Major clofibrate effects on liver and plasma lipids are independent of changes in polyunsaturated fatty acid composition induced by dietary fat.
The effects of clofibrate on the content and composition of liver and plasma lipids was studied in mice fed for 4 wk on diets enriched in n-6 or n-3 polyunsaturated fatty acids (PUFA) from sunflower oil (SO) or fish oil (FO), respectively; both oils were fed at 9% of the diet (dry weight basis). Only FO was hypolipidemic. Both oil regimes led to slightly increased concentrations of phospholipids (PL) and triacylglycerols (TG) in liver as compared with a standard chow diet containing 2% fat. Clofibrate promoted hypolipidemia only in animals fed SO. Its main effect was to enlarge the liver, such growth increasing the amounts of major glycerophospholipids while depleting the TG. SO and FO consumption changed the proportion of n-6 or n-3 PUFA in liver and plasma lipids in opposite ways. After clofibrate action, the PUFA of liver PL were preserved better than in the absence of oil supplementation. However, most of the drug-induced changes (e.g., increased 18:1n-9 and 20:3n-6, decreased 22:6/20:5 ratios) occurred irrespective of lipids being rich in n-6 or n-3 PUFA. The concentration of sphingomyelin (SM), a minor liver lipid that virtually lacks PUFA, increased with the dietary oils, decreased with clofibrate, and changed its fatty acid composition in both situations. Thus, oil-increased SM had more 22:0 and 24:0 than clofibrate-decreased SM, which was significantly richer in 22:1 and 24:1.
Pennacchiotti
G L
GL
Instituto de Investigaciones Bioquímicas de Bahía Blanca, Consejo Nacional de Investigaciones Científicas y Técnicas y Universidad Nacional del Sur, Argentina. grapen@criba.edu.ar
Maldonado
E N
EN
Aveldaño
M I
MI
D000818:Animals; D002994:Clofibrate / Q000494:pharmacology*; D004041:Dietary Fats / Q000494:pharmacology*; D015525:Fatty Acids, Omega-3; D043371:Fatty Acids, Omega-6; D005231:Fatty Acids, Unsaturated / Q000032:analysis* / Q000494:pharmacology; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D050356:Lipid Metabolism; D008055:Lipids / Q000097:blood / Q000737:chemistry; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D010743:Phospholipids / Q000737:chemistry / Q000378:metabolism; D014280:Triglycerides / Q000494:pharmacology
D004041:Dietary Fats; D015525:Fatty Acids, Omega-3; D043371:Fatty Acids, Omega-6; D005231:Fatty Acids, Unsaturated; D000960:Hypolipidemic Agents; D008055:Lipids; D010743:Phospholipids; D014280:Triglycerides; C077446:Pikasol; D002994:Clofibrate